Literature DB >> 30643240

Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis.

Nobuhiro Nakamoto1, Nobuo Sasaki1,2, Ryo Aoki1,3, Kentaro Miyamoto1,4, Wataru Suda5,6, Toshiaki Teratani1, Takahiro Suzuki1,4, Yuzo Koda1,7, Po-Sung Chu1, Nobuhito Taniki1, Akihiro Yamaguchi1, Mitsuhiro Kanamori5, Nobuhiko Kamada8, Masahira Hattori6,9, Hiroshi Ashida10, Michiie Sakamoto11, Koji Atarashi5,12, Seiko Narushima5,12, Akihiko Yoshimura5, Kenya Honda5,12, Toshiro Sato13, Takanori Kanai14,15.   

Abstract

Primary sclerosing cholangitis (PSC) is a chronic inflammatory liver disease and its frequent complication with ulcerative colitis highlights the pathogenic role of epithelial barrier dysfunction. Intestinal barrier dysfunction has been implicated in the pathogenesis of PSC, yet its underlying mechanism remains unknown. Here, we identify Klebsiella pneumonia in the microbiota of patients with PSC and demonstrate that K. pneumoniae disrupts the epithelial barrier to initiate bacterial translocation and liver inflammatory responses. Gnotobiotic mice inoculated with PSC-derived microbiota exhibited T helper 17 (TH17) cell responses in the liver and increased susceptibility to hepatobiliary injuries. Bacterial culture of mesenteric lymph nodes in these mice isolated K. pneumoniae, Proteus mirabilis and Enterococcus gallinarum, which were prevalently detected in patients with PSC. A bacterial-organoid co-culture system visualized the epithelial-damaging effect of PSC-derived K. pneumoniae that was associated with bacterial translocation and susceptibility to TH17-mediated hepatobiliary injuries. We also show that antibiotic treatment ameliorated the TH17 immune response induced by PSC-derived microbiota. These results highlight the role of pathobionts in intestinal barrier dysfunction and liver inflammation, providing insights into therapeutic strategies for PSC.

Entities:  

Mesh:

Year:  2019        PMID: 30643240     DOI: 10.1038/s41564-018-0333-1

Source DB:  PubMed          Journal:  Nat Microbiol        ISSN: 2058-5276            Impact factor:   17.745


  80 in total

Review 1.  Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?

Authors:  Lu Jiang; Bernd Schnabl
Journal:  Physiology (Bethesda)       Date:  2020-07-01

2.  Gut microbiome alterations in type 1 autoimmune pancreatitis after induction of remission by prednisolone.

Authors:  K Kamata; T Watanabe; K Minaga; A Hara; I Sekai; Y Otsuka; T Yoshikawa; A-M Park; M Kudo
Journal:  Clin Exp Immunol       Date:  2020-09-21       Impact factor: 4.330

3.  Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition.

Authors:  Akira Honda; Teruo Miyazaki; Junichi Iwamoto; Takeshi Hirayama; Yukio Morishita; Tadakuni Monma; Hajime Ueda; Seiya Mizuno; Fumihiro Sugiyama; Satoru Takahashi; Tadashi Ikegami
Journal:  J Lipid Res       Date:  2019-10-23       Impact factor: 5.922

Review 4.  Host-microbiota interactions in immune-mediated diseases.

Authors:  William E Ruff; Teri M Greiling; Martin A Kriegel
Journal:  Nat Rev Microbiol       Date:  2020-05-26       Impact factor: 60.633

Review 5.  Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.

Authors:  Daniel M Chopyk; Arash Grakoui
Journal:  Gastroenterology       Date:  2020-06-20       Impact factor: 22.682

Review 6.  Systemic Lupus Erythematosus and dysbiosis in the microbiome: cause or effect or both?

Authors:  Gregg J Silverman; Doua F Azzouz; Alexander V Alekseyenko
Journal:  Curr Opin Immunol       Date:  2019-10-04       Impact factor: 7.486

Review 7.  Novel approaches to liver disease diagnosis and modeling.

Authors:  André G Oliveira; Romina Fiorotto
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

8.  The Gut-Liver Axis in Primary Sclerosing Cholangitis: Are Pathobionts the Missing Link?

Authors:  Steven P O'Hara; Nicholas F LaRusso
Journal:  Hepatology       Date:  2019-05-23       Impact factor: 17.425

9.  Characterization of the gut microbiota in patients with primary sclerosing cholangitis compared to inflammatory bowel disease and healthy controls.

Authors:  Samaneh Ostadmohammadi; Masoumeh Azimirad; Hamidreza Houri; Kaveh Naseri; Ehsan Javanmard; Hamed Mirjalali; Abbas Yadegar; Amir Sadeghi; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Mol Biol Rep       Date:  2021-07-25       Impact factor: 2.316

10.  Dysbiotic gut microbiota in pancreatic cancer patients form correlation networks with the oral microbiota and prognostic factors.

Authors:  Hiroki Matsukawa; Noriho Iida; Kazuya Kitamura; Takeshi Terashima; Jun Seishima; Isamu Makino; Takayuki Kannon; Kazuyoshi Hosomichi; Taro Yamashita; Yoshio Sakai; Masao Honda; Tatsuya Yamashita; Eishiro Mizukoshi; Shuichi Kaneko
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.